- Home
- MLYS vs CAC Comparison
MLYS vs CAC Comparison
Compare MLYS & CAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- CAC
- Stock Information
- Founded
- MLYS 2019
- CAC 1875
- Country
- MLYS United States
- CAC United States
- Employees
- MLYS N/A
- CAC N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- CAC Major Banks
- Sector
- MLYS Health Care
- CAC Finance
- Exchange
- MLYS Nasdaq
- CAC Nasdaq
- Market Cap
- MLYS 526.1M
- CAC N/A
- IPO Year
- MLYS 2023
- CAC 1997
- Fundamental
- Price
- MLYS $10.21
- CAC $45.25
- Analyst Decision
- MLYS Strong Buy
- CAC Hold
- Analyst Count
- MLYS 2
- CAC 3
- Target Price
- MLYS $30.00
- CAC $48.33
- AVG Volume (30 Days)
- MLYS 263.5K
- CAC 87.0K
- Earning Date
- MLYS 03-20-2025
- CAC 01-28-2025
- Dividend Yield
- MLYS N/A
- CAC 3.74%
- EPS Growth
- MLYS N/A
- CAC 21.89
- EPS
- MLYS N/A
- CAC 3.62
- Revenue
- MLYS N/A
- CAC $177,396,000.00
- Revenue This Year
- MLYS N/A
- CAC N/A
- Revenue Next Year
- MLYS N/A
- CAC $10.12
- P/E Ratio
- MLYS N/A
- CAC $12.27
- Revenue Growth
- MLYS N/A
- CAC 10.05
- 52 Week Low
- MLYS $8.58
- CAC $28.62
- 52 Week High
- MLYS $16.91
- CAC $50.07
- Technical
- Relative Strength Index (RSI)
- MLYS 44.53
- CAC 51.55
- Support Level
- MLYS $9.57
- CAC $45.00
- Resistance Level
- MLYS $10.79
- CAC $46.49
- Average True Range (ATR)
- MLYS 0.64
- CAC 1.20
- MACD
- MLYS 0.11
- CAC 0.24
- Stochastic Oscillator
- MLYS 63.98
- CAC 48.77
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.